TLR4 and tuberculosis: GLA, a Th1-inducing synthetic TLR4-agonist adjuvant that is a non-toxic derivative of lipopolysaccharide, has led to improved immunogenicity of investigational vaccines for tuberculosis [15] and influenza [16].